Literature DB >> 30212297

Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement.

Karen M Winkfield1, Jonathan K Phillips1, Steven Joffe1, Michael T Halpern1, Dana S Wollins1, Beverly Moy1.   

Abstract

Research conducted through clinical trials is essential for evaluating new treatment modalities, establishing new standards of cancer care, and ultimately improving and prolonging the lives of patients with cancer. However, participation in trials has been low, and this is attributable to various factors including patient financial barriers. Such financial barriers include the rising cost of cancer care; a lack of transparency in coverage policy; and the perception of ethical, compliance, or institutional impediments to patient financial support. ASCO convened a roundtable discussion with a variety of stakeholders to define the scope of the problem, as well as to identify clinical practice and policy solutions applicable at the institutional and system-wide levels. This statement summarizes key discussions from the ASCO Roundtable, as well as findings from the literature, and provides ASCO's recommendations for overcoming financial barriers that may otherwise prevent participation in clinical trials. These recommendations broadly address the following key areas: (1) improving the policy environment for coverage of clinical trials; (2) facilitating transparency among providers, patients, and payers for trial-related out-of-pocket costs; (3) refuting the specter of inducement to enable targeted financial support for patients; and (4) improving the available data on costs of cancer clinical trials.

Entities:  

Year:  2018        PMID: 30212297     DOI: 10.1200/JCO.18.01132

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  10 in total

1.  Science in the Heartland: Exploring determinants of offering cancer clinical trials in rural-serving community urology practices.

Authors:  Shellie D Ellis; Mugur Geana; Christine B Mackay; Deborah J Moon; Jessie Gills; Andrew Zganjar; Gayle Brekke; J Brantley Thrasher; Tomas L Griebling
Journal:  Urol Oncol       Date:  2019-03-29       Impact factor: 3.498

2.  21 Code of Federal Regulations Part 11-Compliant Digital Signature Solution for Cancer Clinical Trials: A Single-Institution Feasibility Study.

Authors:  Therica M Miller; Jenny Lester; Lorna Kwan; Megha D Tandel; Beth Y Karlan; B J Rimel
Journal:  JCO Clin Cancer Inform       Date:  2020-09

Review 3.  Recruitment and Trial-Finding Apps-Time for Rules of the Road.

Authors:  Stephanie R Morain; Emily A Largent
Journal:  J Natl Cancer Inst       Date:  2019-09-01       Impact factor: 13.506

4.  Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.

Authors:  Julia Foldi; Adriana Kahn; Andrea Silber; Tao Qing; Emily Reisenbichler; Neal Fischbach; Justin Persico; Kerin Adelson; Anamika Katoch; Anees Chagpar; Tristen Park; Adam Blanchard; Kim Blenman; David L Rimm; Lajos Pusztai
Journal:  Clin Cancer Res       Date:  2022-09-01       Impact factor: 13.801

5.  Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials.

Authors:  Ryan W Huey; Goldy C George; Penny Phillips; Revenda White; Siqing Fu; Filip Janku; Daniel D Karp; Aung Naing; Sarina Piha-Paul; Vivek Subbiah; Apostolia M Tsimberidou; Shubham Pant; Timothy A Yap; Jordi Rodon; Funda Meric-Bernstam; Ya-Chen Tina Shih; David S Hong
Journal:  Oncologist       Date:  2021-04-21

6.  Participation of Black Americans in Cancer Clinical Trials: Current Challenges and Proposed Solutions.

Authors:  Muhammad Awidi; Samer Al Hadidi
Journal:  JCO Oncol Pract       Date:  2021-05

7.  Developing a Virtual Equity Hub: Adapting the Tumor Board Model for Equity in Cancer Care.

Authors:  Kelly E Irwin; Naomi Ko; Elizabeth P Walsh; Veronica Decker; Isabel Arrillaga-Romany; Scott R Plotkin; Jeffrey Franas; Emily Gorton; Beverly Moy
Journal:  Oncologist       Date:  2022-07-05       Impact factor: 5.837

8.  Gatekeeping in cancer clinical trials in Canada: The ethics of recruiting the "ideal" patient.

Authors:  Jennifer A H Bell; Mary T Kelly; Karen Gelmon; Kim Chi; Anita Ho; Patricia Rodney; Lynda G Balneaves
Journal:  Cancer Med       Date:  2020-04-20       Impact factor: 4.452

9.  Attitudes towards open-label versus placebo-control designs in oncology randomized trials: A survey of medical oncologists.

Authors:  Igal Kushnir; Mark Clemons; Dean Fergusson; Dominick Bossé; Martin Neil Reaume
Journal:  J Eval Clin Pract       Date:  2022-02-21       Impact factor: 2.336

10.  Demographic and Health Behavior Factors Associated With Clinical Trial Invitation and Participation in the United States.

Authors:  Courtney P Williams; Nicole Senft Everson; Nonniekaye Shelburne; Wynne E Norton
Journal:  JAMA Netw Open       Date:  2021-09-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.